---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-002314"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:31:10.537960+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Chemomab reports 2022 Annual Meeting vote results; all proposals pass

## Summary
- Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.
- Proposal 2: approve amendment to compensation of Dr. Adi Mor (CSO) passed with 83,840,260 FOR.
- Proposal 4: reappoint Somekh Chaikin (KPMG) as auditor approved with 84,152,640 FOR.
- Proposal 3 (equity grants to directors) was withdrawn prior to the meeting.
- Total shares represented: 84,756,220 ordinary (37.16% of outstanding).

## SEC filing metadata
- accession: 0001178913-22-002314
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/0001178913-22-002314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322002314/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-002314
- JSON: https://secwatch.observer/filing/0001178913-22-002314.json
- Plain text: https://secwatch.observer/filing/0001178913-22-002314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.